Human Radiosensitivity and Radiosusceptibility: What Are the Differences?
Laura El Nachef(Inserm), Nicolas Foray(Inserm), Élise Berthel(Inserm), Michel Bourguignon(Centre Hospitalier d'Orsay), P. Combemale(Centre Léon Bérard), Joëlle Al-Choboq(Inserm), Mélanie L. Ferlazzo(Inserm), Juliette Restier-Verlet(Inserm), Pierre Leblond(Centre Oscar Lambret), Adeline Granzotto(Inserm), Audrey Bouchet(Inserm), Laurène Sonzogni(Inserm), S. Pinson(Hôpital Edouard Herriot)
Cited by 73
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188